127 related articles for article (PubMed ID: 11138278)
21. Prognostic value of plasmatic tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal cancer patients.
Fatela-Cantillo D; Fernandez-Suarez A; Moreno MA; Gutierrez JJ; Iglesias JM
Tumour Biol; 2012 Jun; 33(3):825-32. PubMed ID: 22231432
[TBL] [Abstract][Full Text] [Related]
22. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy.
Hathurusinghe HR; Goonetilleke KS; Siriwardena AK
Ann Surg Oncol; 2007 Oct; 14(10):2714-20. PubMed ID: 17602267
[TBL] [Abstract][Full Text] [Related]
23. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
24. Tumor type M2 pyruvate kinase expression in advanced breast cancer.
Lüftner D; Mesterharm J; Akrivakis C; Geppert R; Petrides PE; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5077-82. PubMed ID: 11326672
[TBL] [Abstract][Full Text] [Related]
25. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
26. Tumor M2-Pyruvate Kinase, Matrix Carbonic Anhydrase IX, and Metalloproteinase 9 - Novel Prognostic Markers of Renal Cell Carcinoma.
Amoev ZV; Alyasova AV; Gorshkova TN; Samsonova EI; Strokina EV; Kontorshchikova KN
Sovrem Tekhnologii Med; 2020; 12(2):43-47. PubMed ID: 34513052
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma.
Hegele A; Heidenreich A; Kropf J; von Knobloch R; Varga Z; Hofmann R; Olbert P
Tumour Biol; 2004; 25(3):111-6. PubMed ID: 15361707
[TBL] [Abstract][Full Text] [Related]
29. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
30. Tumour M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study.
Ahmed AS; Dew T; Lawton FG; Papadopoulos AJ; Devaja O; Raju KS; Sherwood RA
Eur J Gynaecol Oncol; 2007; 28(2):103-8. PubMed ID: 17479670
[TBL] [Abstract][Full Text] [Related]
31. Tumor type M2 pyruvate kinase expression in gastric cancer, colorectal cancer and controls.
Zhang B; Chen JY; Chen DD; Wang GB; Shen P
World J Gastroenterol; 2004 Jun; 10(11):1643-6. PubMed ID: 15162541
[TBL] [Abstract][Full Text] [Related]
32. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
33. L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases.
Brinck U; Eigenbrodt E; Oehmke M; Mazurek S; Fischer G
Virchows Arch; 1994; 424(2):177-85. PubMed ID: 8180780
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
[TBL] [Abstract][Full Text] [Related]
35. Tumor M2 pyruvate kinase--determination in breast cancer patients receiving trastuzumab therapy.
Hoopmann M; Warm M; Mallmann P; Thomas A; Göhring UJ; Schöndorf T
Cancer Lett; 2002 Dec; 187(1-2):223-8. PubMed ID: 12359372
[TBL] [Abstract][Full Text] [Related]
36. Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.
El-Abd E; El-Sheikh M; Zaky S; Fayed W; El-Zoghby S
Cancer Biomark; 2017 Aug; 20(2):123-133. PubMed ID: 28869444
[TBL] [Abstract][Full Text] [Related]
37. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
Eigenbrodt E; Basenau D; Holthusen S; Mazurek S; Fischer G
Anticancer Res; 1997; 17(4B):3153-6. PubMed ID: 9329624
[TBL] [Abstract][Full Text] [Related]
38. Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.
Dhar DK; Olde Damink SW; Brindley JH; Godfrey A; Chapman MH; Sandanayake NS; Andreola F; Mazurek S; Hasan T; Malago M; Pereira SP
Cancer; 2013 Feb; 119(3):575-85. PubMed ID: 22864959
[TBL] [Abstract][Full Text] [Related]
39. Enzyme Kinetic Assay to Measure the Activity of Tumor M2 Pyruvate Kinase in Breast Cancer Patients.
Guan M; Tong Y; Liu X; Dong D; Zhou Y
Ann Clin Lab Sci; 2017 Nov; 47(6):676-686. PubMed ID: 29263041
[TBL] [Abstract][Full Text] [Related]
40. Tumor M2-PK levels in haematological malignancies.
Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
